Skip to main content
Caplight Logo









Dunad Therapeutics

Dunad Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://www.dunadtx.com/

Last Round

Strategic

Nov 2, 2021

Total Funding Raised

$30.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Dunad Therapeutics is a biotechnology company that develops next-generation targeted oral protein degradation therapies for oncology and CNS indications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

targeted protein degradationcovalent chemistryTPDdrug discovery platformundruggable targetssmall molecule drugscovalent degradersmolecular glueneurodegenerative diseaseCNS-accessible drugsmono-valent degradersoral medicinesbiotech partnershipsoncologydrug licensingALS therapyParkinson's disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Dunad Therapeutics Comparables

Compare Dunad Therapeutics with similar companies based on industry and business-model similarity.

Dunad Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RDP Pharma AG
87%
General Proximity
87%
Plexium
86%

Dunad Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicNov 2, 2021
SeedMar 23, 2021

Key People

Founding team and executive leadership

Pearl Huang

CEO and President

Executive Team

Dunad Therapeutics Investors

Notable investors and investment history

Dunad Therapeutics investors
InvestorRounds
Epidarex CapitalStrategic, Seed
BioGeneration VenturesStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Job postings surged from 0 to 13 roles, representing 100% of headcount.

  • Jul 4, 2025

    Monthly visitors increased 52% MoM.

Dunad Therapeutics Filings

Explore SEC and related filing metadata, where available.

Dunad Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Dunad Therapeutics's valuation, stock price, and market status.

Is Dunad Therapeutics a public or private company?

Dunad Therapeutics is a private company.

What is the current stock price of Dunad Therapeutics?

Dunad Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Dunad Therapeutics worth (valuation)?

Valuation information for Dunad Therapeutics is not publicly available.

Can I buy Dunad Therapeutics stock?

Dunad Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Dunad Therapeutics's last funding round?

Funding round information for Dunad Therapeutics is not publicly available.

Who are the main investors in Dunad Therapeutics?

Investor information for Dunad Therapeutics is not publicly disclosed.

Will Dunad Therapeutics IPO soon?

No public IPO plans have been announced for Dunad Therapeutics.

How can I track Dunad Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Dunad Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge
Employee Range16
Year Founded2020
Last FundingNov 2, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?